Effective March 31, 2019, FDA began the implementation of an agency reorganization. FDA’s reorganization reflects the agency’s commitment to modernizing its structure to advance its mission to protect and promote public health, and to meet the challenges of rapid innovation across the industries regulated by FDA. The FDA’s reorganization will realign several entities across the agency to promote strategic priorities, and will elevate the role of the centers, offices and field forces.
This organization chart reflects the new structure under which FDA will operate.
The following is the Food and Drug Administration organizational structure depicting the organizational structures reporting to the Commissioner of Food and Drugs within the Office of the Commissioner. The Standard Administrative code (Alphanumeric sequence of characters beginning with the letter D) is represented in alphabetical order within the hierarchy of their office component from top to bottom and left to right.
Each organizational component will be depicted in the following standard format:
Title of organization. Position title of the head of the organizational component. Public Health Service rank if any, first name, middle initial if any, last name, post graduate degrees if any, and if the individual is designated as acting.
Office of the Commissioner Commissioner of Food and Drugs Robert M. Califf, MD
Reports directly to the Commissioner of Food and Drugs Principal Deputy Commissioner Janet Woodcock, MD
Chief of Staff Julia Tierney, JD (DCA)
Reports directly to the General Counsel of HHS Office of the Chief Counsel Chief Counsel Mark Raza, JD (DCAA)
Reports directly to the Commissioner of Food and Drugs Office of the Executive Secretariat Director Martina Varnado (DCAB)
Office of the Counselor to the Commissioner Counselor to the Commissioner Vacant (DCAC)
Office of Digital Transformation Chief Information Officer Vidyut Desai (DCAD)
Center for Biologics Evaluation and Research Director Peter Marks, MD, PhD (DCB)
Center for Devices and Radiological Health Director Jeffrey Shuren, JD, MD (DCC)
Center for Drug Evaluation and Research Director Patrizia Cavazzoni, MD (DCD)
Center for Food Safety and Applied Nutrition Director Susan Mayne, PhD (DCE)
Center for Tobacco Products Director Brian King (DCF)
Center for Veterinary Medicine Director Steven Solomon, DVM, MPH (DCG)
Oncology Center of Excellence Director Richard Pazdur, MD (DCH)
Office of Regulatory Affairs Associate Commissioner Judy McMeekin, PharmD (DCI)
Office of Clinical Policy and Programs Director Thinh Nguyen (Acting) (DCJ)
Office of External Affairs Associate Commissioner Erica Jefferson (DCK)
Office of Food Policy and Response Deputy Commissioner Frank Yiannas (DCL)
Office of Minority Health and Health Equity Associate Commissioner RADM Richardae Araojo, PharmD (DCM)
Office of Operations Deputy Commissioner for Operations and Chief Operating Officer James Sigg (DCN)
Office of Policy, Legislation, International Affairs Deputy Commissioner for Policy, Planning, Legislation, and Analysis Andi Fristedt (DCO)
Office of the Chief Scientist Chief Scientist Namandje Bumpus (Acting)
Reports directly to the Office of the Chief Scientist
National Center for Toxicological Research Director Tucker Patterson, PhD (Acting) (DCP)
Reports directly to the Commissioner of Food and Drugs
Office of Women’s Health Associate Commissioner Kaveeta Vasisht, MD, PharmD (DCQ)
Comentários